•Dr. Viribay adds more than 16 years of international experience in molecular biology and biotechnology markets
•Strong focus on boosting international sales, mainly in Europe and the US
Madrid, Spain and Heidelberg, Germany, April 22nd, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that Dr. Miguel-Antonio Viribay has joined SYGNIS and will assume responsibility for the further development, implementation and execution of sales and marketing strategies as Vice President Sales and Marketing.
Dr. Viribay has over 16 years of successful international experience in the biotech industry. He held executive positions in the sales and marketing departments of leading American companies operating in Southern Europe, such as Life Technologies, Agilent or, more recently, Thermo Fisher. All these companies specialize in products for molecular biology and next generation sequencing, priority areas also for SYGNIS. Mr. Viribay holds a PhD in Molecular Genetics. In his newly created position as Vice President Sales and Marketing, Dr. Viribay will be responsible for deepening the marketing approach, based on direct sale of SYGNIS products as well as on agreements with SYGNIS’ distribution partners worldwide, developing new business and sales strategies, and promoting online sales in order to boost international sales, especially in the European and US markets.
“We are very much looking forward to welcoming Dr. Viribay to SYGNIS”, Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Dr. Viribay’s extensive experience in world-wide marketing and sales in the biotechnology industry combined with his scientific excellence in molecular science will support and further enhance SYGNIS position as a leading provider of innovative products and technologies for DNA amplification and sequencing in growth markets, especially in Europe and the US. Now that we have expanded our scope of business and are selling our own products, Dr. Viribay will play a key role as we continue to pursue our growth strategy and position our products for long-term success.”
“I am very pleased to join SYGNIS at this exciting point in its journey,” Dr. Miguel-Antonio Viribay added. “With the launch of its second product line in just seven months the company paved the ground for future success and I am very much looking forward to contribute to its next phase of growth and joining this proven and dynamic management team.”
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi®, licensed to an industry leading partner and two own product lines on the market: TruePrime™ based on its proprietary TruePrime™ technology for whole genome amplification and SunScript™ Reverse Transcriptase to convert genetic information from RNA molecules back to DNA. Both product lines are addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications.
Help employers find you! Check out all the jobs and post your resume.
